Operation Warp Speed

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, Solid lipid nanoparticle, RNA, SaRNA, Development, Emergent, CMO, CMOS, BioNTech, MicroRNA, LNP, Plasmid, Merck, Diosynth, CGMP, Nucleic acid, Organization, Clinical trial, Research, Operation Warp Speed, Oncology, PTS, Merck Group, COVID-19, Commercial, AMRI, CDMO, Safety, CAGR, Technology, Viral Research and Diagnostic Laboratories, Vaccine, SM-102, Partnership, LPN, International, Nanoparticle, Prevalence, Contract, Drug development, FDB, Industry, Attention, Fine chemical, Pharmaceutical industry, Others

According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles (LNPs) CDMO services in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA, Emergent, Nucleic acid, Organization, Research, COVID-19, LNP, SM-102, LPN, Drug development, Solid lipid nanoparticle, Development, Plasmid, Merck, Partnership, PTS, Oncology, Merck Group, Commercial, Safety, Technology, Viral Research and Diagnostic Laboratories, International, Nanoparticle, Prevalence, SaRNA, CMO, CMOS, BioNTech, MicroRNA, Diosynth, Clinical trial, AMRI, CDMO, Attention, RNA transfection, CGMP, Operation Warp Speed, Vaccine, Contract, FDB, Industry, Fine chemical, Pharmaceutical industry, Others

This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.

Key Points: 
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Lipid nanoparticles provide the prospect of developing new therapies due to their unique size dependent features.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

General Gustave Perna Joins DEFCON AI as Chief Operating Officer

Retrieved on: 
Thursday, October 27, 2022
Technology, Health, Transport, Software, Military, Artificial Intelligence, Government Technology, Logistics, Supply Chain Management, Defense, Contracts, COVID-19, General officer, DEFCON, Solution, COVID-19, Technology, Commander, Instagram, Perna, Army Materiel Command, LinkedIn, United States Army Materiel Command, Partnership, Decision-making, Vaccine, U.S. Department of Defense Strategy for Operating in Cyberspace, COO, Department, Army, Defense, Red Cell, Leadership, Operation Warp Speed, Twitter, Pharmaceutical industry, Management, Public relations, United

DEFCON AI , (DEFCON), a cutting-edge software company building next-generation tools for the modern military mobility environment, announced that General Gustave Perna has joined the company as its Chief Operating Officer.

Key Points: 
  • DEFCON AI , (DEFCON), a cutting-edge software company building next-generation tools for the modern military mobility environment, announced that General Gustave Perna has joined the company as its Chief Operating Officer.
  • General Perna is a retired four-star general who most recently served as the chief operating officer of Operation Warp Speed, the federal governments public-private partnership for the accelerated development, manufacturing, and distribution of the COVID-19 vaccines.
  • Im proud to be working with General Perna to develop the tools needed to respond efficiently and effectively to future events.
  • We are honored and humbled that General Perna has joined DEFCON, said the company's co-founder/CEO and Red Cell Partners President Yisroel Brumer.

MD Helicopters Announces New Ownership and Leadership

Retrieved on: 
Friday, September 9, 2022
Aircraft, United States Army Materiel Command, Partnership, COVID-19, Operation Warp Speed, AMC, CEO, Customer support, Safety, Boeing Rotorcraft Systems, AGC Aerospace & Defense, Nation, Army, Government, Financial management, MDH, Blackstone, Ownership, Board, Leadership, MD Helicopters, LinkedIn, Senior, Organization, Partner, The Nation, MD, Hawker Beechcraft, Commander, Army Materiel Command, Instagram, Board of directors, Therapy, Insurance, LLC, Twitter, Sikorsky Aircraft, Law enforcement, Hughes Helicopters, COVID-19 vaccine, VIP, Growth, Industry, Management, Engineering, Facebook, Boeing

MESA, Ariz., Sept. 9, 2022 /PRNewswire/ -- MD Helicopters, LLC (MDH) is pleased to announce new ownership and leadership. An investment consortium led by MBIA Insurance Corp., Bardin Hill, and MB Global Partners has acquired the company and established new leadership.  

Key Points: 
  • MESA, Ariz., Sept. 9, 2022 /PRNewswire/ -- MD Helicopters, LLC (MDH) is pleased to announce new ownership and leadership.
  • Brad Pedersen will lead the team as MD Helicopters' President and CEO.
  • Pedersen started his career at Hughes Helicopters and has almost 20 years of Engineering and Leadership experience with the MD Helicopter product lines.
  • To learn more about MD Helicopters, visit us at mdhelicopters.com , or follow us on Facebook , Twitter , Instagram , and LinkedIn .

Meridian Clinical Research Appoints Chief Medical Officer, Adds New Medical Director

Retrieved on: 
Tuesday, August 9, 2022
The New England Journal of Medicine, Medicine, Principal, Documentation, NIH, OWS, BARDA, National, Research, Principal investigator, Patient, Biomedical Advanced Research and Development Authority, COVID-19, CPI, DSMB, Program, Operation Warp Speed, Physician, Cros, Medical director, Development, Pharmaceutical industry, Medical device, Meridian, MD

OMAHA, Neb., Aug. 9, 2022 /PRNewswire-PRWeb/ -- Meridian Clinical Research, a leading multi-specialty investigative research site network, has promoted Brandon Essink, MD, CPI, to Chief Medical Officer, and promoted Shishir Khetan, MD, to Medical Director. Both physicians will continue to serve as Principal Investigators for clinical trials at Meridian. The doctors will support new and existing principal investigators across Meridian's therapeutically diverse network, which has grown to 35 sites.

Key Points: 
  • Meridian Clinical Research, a leading multi-specialty investigative research site network, has promoted Brandon Essink, MD, CPI, to Chief Medical Officer, and Shishir Khetan, MD, to Medical Director.
  • OMAHA, Neb., Aug. 9, 2022 /PRNewswire-PRWeb/ -- Meridian Clinical Research , a leading multi-specialty investigative research site network, has promoted Brandon Essink, MD, CPI , to Chief Medical Officer, and promoted Shishir Khetan, MD , to Medical Director.
  • Both physicians will continue to serve as Principal Investigators for clinical trials at Meridian.
  • Dr. Khetan is also a Regional Medical Director and Virtual Medical Director for Privia Medical Group, and serves on the Privia Health and Privia Quality Network Board of Governors.

Asahi Kasei Bioprocess to Showcase Award-winning MOTIV™ Buffer Management Technology for Pharmaceutical Manufacturing at ACHEMA 2022

Retrieved on: 
Wednesday, July 27, 2022
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Asahi Kasei, R, Data collection, Bioprocess, Solution, Family, Multimedia, Marketing, IBF, Technology, Patient, Farm, Operation Warp Speed, Buffer, Medicine, Mobile phone, RELX

Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV Buffer Management Technology at ACHEMA 2022 in Frankfurt this August.

Key Points: 
  • Asahi Kasei Bioprocess America, subsidiary of diversified Japanese multinational company Asahi Kasei, will be featuring their MOTIV Buffer Management Technology at ACHEMA 2022 in Frankfurt this August.
  • MOTIV can blend buffers from concentrates in small, single-use bags and is controlled with sensors to maintain and assure precision.
  • One of our strengths is not only having an innovative product, but also an extensive family of MOTIV systems to choose from.
  • 1 The OCELOT System Control is an Asahi Kasei Bioprocess proprietary technology that integrates and/or interfaces with plant-wide control systems in a universally compatible format, allowing for far-reaching data collection and analysis.

The Hargan Group Launches New Independent Government Relations and Public Affairs Venture

Retrieved on: 
Tuesday, July 19, 2022
Cornell University, GLOBE, Interview, Twitter, Board, HHS, Policy, Goal, Public policy, Organization, University Hospitals Cleveland Medical Center, Government, Politics, Vanderbilt University, Operation Warp Speed, Pharmaceutical industry, Public relations

ARLINGTON, Va., July 19, 2022 (GLOBE NEWSWIRE) -- The Hargan Group today announced the launch of an independent government relations and public affairs entity, Hargan Strategies.

Key Points: 
  • ARLINGTON, Va., July 19, 2022 (GLOBE NEWSWIRE) -- The Hargan Group today announced the launch of an independent government relations and public affairs entity, Hargan Strategies.
  • The Hargan Group, founded in 2021 by former HHS Deputy Secretary Eric Hargan, is a healthcare consulting firm focused on regulatory, public policy and healthcare investment issues.
  • Hargan Strategies is an exciting new expansion and will be led by Emily Duke Hargan.
  • Emily Duke Hargan has 25 years of experience in government affairs, public policy, and fundraising.

Bending the Cost Curve in End-Stage Kidney Disease

Retrieved on: 
Tuesday, June 21, 2022
Chronic kidney disease, Department, University Hospitals Cleveland Medical Center, Government, Artificial intelligence, CEO, Lifeline, Hargan, Entrepreneurship, NHS, United States Department of Health and Human Services, Unitary state, Medicare, Cost curve, 21st Century Cures Act, National, Boston University, CKD, ESKD, Operation Warp Speed, Partnership, Dialysis, Patient, Air force, Board, HHS, Awareness, Andrew Kerr (festival co-founder), Human services, Organization, Public policy, Medicine, Health insurance, Alió, Intermountain

BROOMFIELD, Colo., June 21, 2022 /PRNewswire/ -- Alio and The Hargan Group are pleased to announce they will host a webinar "Bending the Cost Curve in End-Stage Kidney Disease." The webinar will take place on Tuesday, July 12th at 2pm EDT, and feature both Alio Co-founder and CEO, David Kuraguntla, and former US Deputy Secretary of Health and Human Services, Eric Hargan.

Key Points: 
  • BROOMFIELD, Colo., June 21, 2022 /PRNewswire/ -- Alio and The Hargan Group are pleased to announce they will host a webinar "Bending the Cost Curve in End-Stage Kidney Disease."
  • If you're interested in joining the Alio payer webinar, "Bending the Cost Curve in End-Stage Kidney Disease," you may register here .
  • Drawing on his experience, he began to explore the potential of noninvasive wearables for conditions like End Stage Kidney Disease (ESKD) and started Alio.
  • Currently, Alio uses its SmartPatchTM technology to monitor individuals with end stage kidney disease (ESKD) undergoing dialysis.

Moderna and Thermo Fisher Scientific Honored for COVID-19 Vaccine Efforts

Retrieved on: 
Thursday, April 14, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Applied Biosystems, PPD, Infection, Biomedical Advanced Research and Development Authority, Thermo Fisher Scientific, Patheon, Pharmaceutical Services Negotiating Committee, COVID-19, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Fisher Scientific, Food, Science, National Birth Defects Prevention Network, National, Invitrogen, Vaccine, Laboratory, COVE, National Institute, Partnership, RNA transfection, COVID, Operation Warp Speed, Health, Mindful Scientific Inc., Pharmaceutical industry, Phase, Moderna

The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally, were named Clinical Research Team of the Year during the 2021 Citeline Awards.

Key Points: 
  • The PPD clinical research business of Thermo Fisher Scientific and Moderna, whose pioneering mRNA vaccine for COVID has been administered to hundreds of millions globally, were named Clinical Research Team of the Year during the 2021 Citeline Awards.
  • As Modernas clinical research organization partner, the PPD team, now part of Thermo Fisher, supported Modernas mRNA-1273-P301 vaccine trials, including its pivotal Phase III COVE study.
  • This recognition honors our strong collaboration with Moderna and reinforces our shared commitment to develop life-saving vaccines and therapies, said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

Lieutenant General (Retired) Paul Ostrowski, Former Principal Military Deputy to Assistant Secretary of the Army, Acquisition, Logistics, and Technology (ASA ALT) Joins Vita Inclinata As Senior Advisor

Retrieved on: 
Tuesday, March 22, 2022
Adoption, National Defense Research Committee, Principal, General officer, Brings, United States service academies, Government, Capitol Hill, Mississippi Industrial College, PEO, CEO, United States Army Acquisition Corps, Industry, Congress, Army, Senior advisor, Armed, Operation Warp Speed, Special operations, Time, COVID-19, Distribution, Weather, Strategic planning, Acquisition, Management, Science, United States Army

BROOMFIELD, Colo., and WASHINGTON, March 22, 2022 /PRNewswire/ -- Vita Inclinata (Vita), developer and producer of helicopter and crane load stabilization and precision hardware, today announced retired three-star General Officer Paul Ostrowski, U.S. Army, has joined the company as a Senior Advisor. A known Capitol Hill entity with extensive Congressional

Key Points: 
  • "In near-peer conflicts, the U.S. military must field technology that improves our ability to operate quickly and effectively.
  • "My previous experience evaluating and fostering emerging technologies led me to Vita's technology as the team really caught my attention.
  • I look forward to providing my full support in driving the accelerated development and fielding of these critical products."
  • A friend's death during a rescue operationwith a helicopter close but unable to stabilize due to weather and terrainwas the genesis of Vita Inclinata.